Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Compare the Efficacy of (Rifaximin + Mebeverine), (Rifaximin + Amitriptyline), and (Rifaximin + Psyllium Husk) in Irritable Bowel Syndrome Associated With Diarrhea

NCT05867550 is registered in ClinicalTrials.gov with Bahria University as lead sponsor.

NCT NCT05867550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05867550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Compare the Efficacy of (Rifaximin + Mebeverine), (Rifaximin + Amitriptyline), and (Rifaximin + Psyllium Husk) in Irritable Bowel Syndrome Associated With Diarrhea
Lead sponsor
Bahria University
Phase
Phase 4
Overall status
Completed
Start date
January 3, 2023
Completion date
June 10, 2023
Enrollment
162 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with diarrhea